In an adult with high‑energy blunt trauma, moderate traumatic brain injury (Glasgow Coma Scale 13), suspected high cervical spinal injury causing neurogenic shock with bradycardia, hypotension, and quadriparesis, which chronotropic agents are appropriate and how should epinephrine be utilized?

Chronotropic Agents and Epinephrine Use in Neurogenic Shock from Cervical Spinal Cord Injury

In neurogenic shock from high cervical spinal cord injury, atropine is ineffective due to unopposed parasympathetic tone from sympathetic disruption; use epinephrine infusion (0.05-2 mcg/kg/min) as the first-line chronotropic and vasopressor agent, with aminophylline or theophylline as alternative chronotropic options if bradycardia persists despite adequate blood pressure support. 1, 2

Why Atropine Fails in Spinal Cord Injury

Atropine is ineffective for bradycardia in high cervical spinal cord injury because the mechanism differs fundamentally from typical bradycardia. The injury causes acute loss of sympathetic tone (not excessive parasympathetic activity that atropine could block), resulting in unopposed parasympathetic stimulation. 1, 2 This is similar to post-heart transplant denervation where atropine also fails.

Common pitfall: Repeatedly dosing atropine in neurogenic shock wastes critical time. The bradycardia is refractory to atropine and other standard adrenergic drugs. 2

First-Line Agent: Epinephrine

Epinephrine infusion is the preferred chronotropic and vasopressor agent for neurogenic shock with bradycardia and hypotension:

• Dosing: Start at 0.05 mcg/kg/min IV infusion, titrate up to 2 mcg/kg/min to achieve target MAP 3
• Target MAP: Maintain MAP ≥80 mmHg in patients with traumatic brain injury (which commonly coexists with cervical spine injury) 4, 5
• Titration: Adjust every 10-15 minutes in increments of 0.05-0.2 mcg/kg/min 3
• Weaning: After stabilization, decrease incrementally every 30 minutes over 12-24 hours 3

Why Epinephrine Works

Epinephrine provides both:

• Chronotropic effect (β1-agonism increases heart rate)
• Vasopressor effect (α-agonism restores vascular tone lost from sympathetic disruption)

This dual action addresses both components of neurogenic shock simultaneously. 6 Case reports confirm successful hemodynamic stabilization with epinephrine in cervical spinal cord injury patients. 7

Push-Dose Epinephrine Considerations

The 2025 AHA guidelines note that push-dose epinephrine (boluses of 5-20 mcg) has gained popularity for acute bradycardia with hypotension, though specific evidence for bradycardia is limited. 6 Critical warning: Medication errors and adverse hemodynamic effects have been reported with push-dose vasopressors—correct dosing is essential. 6

Alternative Chronotropic Agents

Methylxanthines (Aminophylline/Theophylline)

These are the most evidence-based alternatives specifically for spinal cord injury bradycardia:

• Mechanism: Adenosine receptor blockade targets the underlying pathology of unopposed parasympathetic stimulation 1, 2
• Evidence: Three case series (2-6 patients each) showed beneficial heart rate effects and avoidance of permanent pacemaker implantation 1, 2
• Duration: Usually withdrawn after 4-6 weeks; side effects are rare 1, 2
• Advantage: Specifically addresses the parasympathetic dominance unique to spinal cord injury 8

Dopamine

• Dosing: Continuous infusion titrated to effect 6
• Evidence: A randomized feasibility study comparing dopamine to transcutaneous pacing in atropine-refractory bradycardia found no difference in survival to discharge 6
• Consideration: May be preferred if bradycardia is the dominant problem over hypotension 9
• Limitation: Associated with more arrhythmias than norepinephrine in shock states 9

Transcutaneous Pacing

When medications fail or IV access is unavailable, transcutaneous pacing is a reasonable bridge therapy:

• Can be initiated immediately while establishing vascular access 6
• Often painful in conscious patients—may require sedation (challenging in TBI patients) 6
• Critical limitation: Achieving and maintaining true electrical and mechanical capture is difficult; false capture is common 6
• Should be considered a temporizing measure until transvenous pacing or definitive treatment 1

Clinical Algorithm for Neurogenic Shock with Bradycardia

1. Recognize the pattern: Hypotension + bradycardia (not reflex tachycardia) + quadriparesis = neurogenic shock 7

2. Do NOT waste time with atropine in confirmed high cervical injury 1, 2

3. Start epinephrine infusion immediately:

   • Begin at 0.05 mcg/kg/min
   • Target MAP ≥80 mmHg (especially with concurrent TBI) 4, 5
   • Titrate every 10-15 minutes as needed 3

4. If bradycardia persists despite adequate MAP:

   • Consider adding aminophylline or theophylline for chronotropic support 1, 2, 8
   • Alternative: Switch to or add dopamine infusion 6

5. If medications fail and shock persists:

   • Initiate transcutaneous pacing as bridge 6
   • Arrange for transvenous pacing if needed beyond acute phase 1

Critical Caveats

• Cardiac arrest risk: 16% of patients with severe cervical spinal injury experience cardiac arrest (usually asystole) in the first 2-4 weeks 1, 2
• Common triggers: Tracheal suctioning and patient repositioning can precipitate severe bradycardia episodes 1, 2
• High injury level predicts intervention need: C1-C5 injuries require cardiovascular interventions in 24% of cases vs. only 5% for C6-C7 injuries 10
• Concurrent TBI: Maintain higher MAP targets (≥80 mmHg) to preserve cerebral perfusion pressure 4, 5
• Avoid permissive hypotension: Strategies acceptable in hemorrhagic shock are contraindicated with brain or spinal cord injury 4, 5

Monitoring Priorities

• Continuous cardiac monitoring for arrhythmias (epinephrine and dopamine both increase risk)
• Frequent MAP assessment—consider arterial line placement
• Urine output and lactate clearance as perfusion markers
• Watch for complications: myocardial strain, arrhythmias, excessive vasoconstriction 11

The evidence strongly supports epinephrine as first-line therapy due to its dual chronotropic and vasopressor effects, with methylxanthines offering a unique mechanistic advantage for persistent bradycardia in this specific population. 1, 2, 3